Aravax Pty Ltd
Aravax is developing the first safe, convenient and disease-modifying treatment for peanut allergy with lead product (PVX108). This solution has the potential to revolutionise the treatment of peanut allergies and have life-changing impacts for the health and wellbeing for those living with condition.
Year Established: 2014
Lead Researcher: Robyn O’Hehir
CEO: Pascal Hickey
Website: aravax.com.au